What spatial biology actually measures — and why it matters

Spatial biology maps molecular information — including gene expression, protein distribution, and epigenetic marks — to precise physical locations within intact tissue samples. Unlike bulk sequencing, which averages signals across millions of cells, or even single-cell sequencing, which loses positional context during tissue dissociation, spatial biology preserves the architectural relationships between cells and their microenvironments. This positional fidelity is what makes the technology scientifically distinct and commercially valuable.

The central question spatial biology answers is not simply “which genes are expressed?” but “where in the tissue are they expressed, by which cell types, and in what relationship to neighbouring cells?” This spatial context is critical for understanding tumour heterogeneity, inflammatory microenvironments, neurodegenerative lesion architecture, and developmental biology — domains where tissue organisation is inseparable from function.

The field has matured rapidly from proof-of-concept academic methods to commercial platforms capable of profiling thousands of genes simultaneously across whole tissue sections. According to Nature, spatial transcriptomics was named Method of the Year in 2020, signalling the scientific community’s recognition of its transformative potential — and the commercial race that has followed has been intense.

The four platform categories defining the 2026 landscape

The 2026 spatial biology technology landscape is organised around four broad platform categories, each with distinct underlying principles, resolution characteristics, throughput profiles, and IP dynamics. Understanding these distinctions is essential for R&D strategy and competitive intelligence.

1. Spatial transcriptomics

Spatial transcriptomics platforms capture RNA expression profiles while preserving spatial coordinates. Two dominant technical approaches have emerged: sequencing-based methods, which use barcoded capture arrays or in situ ligation to assign transcripts to spatial positions, and imaging-based methods, which use fluorescent in situ hybridisation (FISH) variants to visualise individual RNA molecules directly in tissue. The sequencing-based approach offers whole-transcriptome coverage; the imaging-based approach offers higher spatial resolution, often reaching single-molecule sensitivity.

2. Spatial proteomics

Spatial proteomics localises proteins within tissue using antibody-based detection combined with spatial readout. Multiplexed ion beam imaging (MIBI), imaging mass cytometry (IMC), and cyclic immunofluorescence (cycIF) platforms can simultaneously detect dozens to hundreds of protein targets in a single tissue section. This capability is particularly powerful for characterising the tumour immune microenvironment and for biomarker discovery in complex diseases.

3. Multiplexed tissue imaging

Multiplexed imaging platforms extend conventional immunohistochemistry and immunofluorescence to enable simultaneous detection of large numbers of biomarkers — sometimes exceeding 100 targets — within the same tissue section. These platforms bridge the gap between routine pathology workflows and high-dimensional spatial profiling, making them attractive for translational and clinical research settings.

4. Spatial multi-omics

Spatial multi-omics platforms integrate two or more molecular layers — such as RNA and protein, or RNA and chromatin accessibility — within the same spatial framework. This integration provides a more complete picture of cellular state and regulatory biology than any single modality alone. As of 2026, spatial multi-omics remains technically challenging but represents the field’s most ambitious frontier, attracting significant academic and commercial R&D investment.

Where the IP battles are being fought

Patent activity in spatial biology has accelerated markedly over the past five years, reflecting the field’s transition from academic curiosity to high-value commercial technology. The IP landscape is complex, with filings concentrated in several distinct technical domains that correspond to the core steps of a spatial biology workflow.

Probe and capture chemistry

The design of oligonucleotide probes, capture arrays, and barcoding schemes represents one of the most intensely contested areas of spatial biology IP. These foundational elements determine the sensitivity, specificity, and scalability of spatial readouts. Patent claims in this area often cover specific probe architectures, ligation chemistries, and array fabrication methods — and are frequently the subject of litigation and licensing negotiations among platform developers.

Tissue processing and sample preparation

Sample preparation is a critical and often underappreciated source of IP value. Methods for tissue fixation, permeabilisation, sectioning, and antigen retrieval that are compatible with spatial profiling workflows are protected by a growing body of patents. Freedom-to-operate analysis in this area is particularly important for organisations developing reagent kits or sample preparation instruments.

Imaging hardware and optical systems

High-resolution, high-throughput imaging systems capable of resolving individual RNA molecules or protein signals across large tissue areas represent a significant hardware IP domain. Patents in this area cover optical configurations, scanning architectures, illumination schemes, and detector designs. Several major instrument manufacturers have established substantial patent portfolios here, creating meaningful barriers to entry.

Computational analysis and bioinformatics

Software and algorithmic IP is an increasingly important component of the spatial biology landscape. Methods for spatial data deconvolution, cell-type assignment, neighbourhood analysis, and integration with single-cell reference atlases are being patented alongside traditional hardware and reagent claims. According to WIPO, software-implemented inventions in life science informatics have grown as a share of total biotech filings, and spatial biology is no exception.

“The spatial biology patent landscape spans probe chemistry, tissue processing, imaging hardware, and computational pipelines — making freedom-to-operate analysis a multi-dimensional challenge for any new market entrant.”

For IP professionals and R&D strategists, monitoring this multi-domain patent landscape requires tools capable of searching across technology classes simultaneously. The European Patent Office and USPTO have both seen increased spatial biology filing volumes, with applicants ranging from large life science instrument companies to university spinouts and dedicated spatial biology startups.

Spatial biology’s expanding role in drug discovery and clinical translation

Spatial biology is increasingly embedded in drug discovery workflows, providing mechanistic insight that bulk and single-cell methods cannot offer. By resolving the spatial organisation of cell types within diseased tissue, spatial platforms help researchers identify the precise cellular and microenvironmental contexts in which disease-driving biology occurs — and where therapeutic intervention is most likely to be effective.

Target identification and validation

Traditional target identification relies heavily on bulk transcriptomics or proteomics, which can obscure the cell-type-specific or spatially restricted expression of potential drug targets. Spatial biology allows researchers to confirm that a target of interest is expressed in the right cell type, in the right tissue compartment, and in the right disease state — reducing the risk of late-stage clinical failure due to poor target validation.

Tumour microenvironment characterisation

Oncology is currently the largest application area for spatial biology, driven by the recognition that tumour response to immunotherapy is strongly influenced by the spatial organisation of immune and stromal cells within the tumour microenvironment. Spatial profiling of tumour biopsies can identify immune cell exclusion patterns, stromal barriers, and immune cell activation states that predict therapeutic response — information that is directly actionable for patient stratification and biomarker development.

Biomarker discovery and companion diagnostics

Spatial biomarkers — molecular signatures defined not just by expression level but by spatial distribution within tissue — represent a new class of diagnostic readout. Several pharmaceutical companies and diagnostic developers are actively building spatial biomarker programmes with the aim of developing companion diagnostics that can predict response to targeted therapies or immunotherapies. This application area is expected to drive significant commercial growth in spatial biology over the next five years.

Remaining technical barriers and the road ahead

Despite significant commercial progress, spatial biology in 2026 still faces a set of technical and operational challenges that limit its routine adoption in clinical and high-throughput research settings. Addressing these barriers is the central focus of both academic research programmes and commercial R&D investment.

Resolution versus throughput trade-offs

Achieving single-cell or sub-cellular resolution across large tissue areas at scale remains technically demanding. Imaging-based platforms can achieve single-molecule resolution but are limited in throughput; sequencing-based platforms offer higher throughput but typically at lower spatial resolution. Bridging this gap — delivering both resolution and scale — is a key engineering challenge that multiple platform developers are actively pursuing through next-generation instrument and chemistry design.

Data volume and computational infrastructure

High-plex spatial experiments generate data volumes that challenge standard laboratory informatics infrastructure. A single spatial transcriptomics experiment on a whole tissue section can produce terabytes of raw imaging data. Downstream analysis — cell segmentation, transcript assignment, spatial statistics, and integration with external reference datasets — requires significant computational resources and specialised bioinformatics expertise that many research groups do not have in-house.

Standardisation and cross-platform comparability

The absence of agreed standards for spatial biology data formats, quality metrics, and analysis workflows makes it difficult to compare results across platforms or aggregate data from multiple studies. Standardisation efforts are underway within the scientific community, and bodies such as ISO are beginning to engage with the life science measurement community on spatial biology reference standards — but consensus remains some years away.

Clinical translation pathway

Translating spatial biology from research tool to clinical diagnostic faces regulatory, reimbursement, and workflow integration challenges. Regulatory agencies including the US FDA have not yet established clear frameworks for spatial biomarker-based companion diagnostics, and the complexity of spatial data interpretation poses challenges for pathology laboratory adoption. These barriers are not insurmountable, but they mean that routine clinical spatial biology is likely still several years from widespread implementation.

“Standardisation of spatial biology data formats and analysis workflows is the field’s most pressing infrastructural challenge — without it, the promise of multi-study data aggregation and AI-driven biomarker discovery cannot be fully realised.”

For innovation leaders tracking this space, the key strategic questions are: which platform architecture will achieve the best resolution-throughput balance, which IP positions are most defensible, and which application areas will reach clinical adoption first. PatSnap Eureka’s AI-powered patent search and landscape analysis tools provide the intelligence infrastructure needed to answer these questions in real time, drawing on PatSnap’s comprehensive IP intelligence capabilities across more than 120 countries.